Impact BioMedical, INC. Increase (Decrease) in Accounts Payable
Impact BioMedical, INC. (IBO) reported Increase (Decrease) in Accounts Payable of $120.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-07
- Impact BioMedical, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $93.00K.
- Impact BioMedical, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $27.00K.
- Impact BioMedical, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $607.00K.
- Impact BioMedical, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $22.00K, a 46.67% increase year-over-year.
- Impact BioMedical, INC. increase (decrease) in accounts payable for fiscal 2025 was $470.00K.
- Impact BioMedical, INC. increase (decrease) in accounts payable for fiscal 2024 was -$436.00K, a 248.81% decline from fiscal 2023.
- Impact BioMedical, INC. increase (decrease) in accounts payable for fiscal 2023 was $293.00K, a 30.90% decline from fiscal 2022.
- Impact BioMedical, INC. increase (decrease) in accounts payable for fiscal 2022 was $424.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $120.00K 10-Q · filed 2026-08-07 | $727.00K derived: sum of 3 quarters · filed 2026-08-07 | $749.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $27.00K 10-Q · filed 2026-05-12 | $634.00K derived: sum of 2 quarters · filed 2026-05-12 | $656.00K derived: sum of 3 quarters · filed 2026-05-12 | $595.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $607.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $629.00K derived: sum of 2 quarters · filed 2026-03-11 | $568.00K derived: sum of 3 quarters · filed 2026-08-07 | $470.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$39.00K derived: sum of 2 quarters · filed 2026-08-07 | -$137.00K 10-Q · filed 2025-11-07 | -$742.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | -$61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$159.00K 10-Q · filed 2026-08-07 | -$764.00K derived: sum of 3 quarters · filed 2026-08-07 | -$749.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$98.00K 10-Q · filed 2026-05-12 | -$703.00K derived: sum of 2 quarters · filed 2026-05-12 | -$688.00K derived: sum of 3 quarters · filed 2026-05-12 | -$725.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$590.00K derived: sum of 2 quarters · filed 2026-03-11 | -$627.00K derived: sum of 3 quarters · filed 2026-03-11 | -$436.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$22.00K derived: sum of 2 quarters · filed 2025-11-07 | $169.00K 10-Q · filed 2025-11-07 | $525.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $154.00K 10-Q · filed 2025-08-14 | $510.00K derived: sum of 3 quarters · filed 2025-08-14 | $685.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $191.00K 10-Q · filed 2025-05-14 | $547.00K derived: sum of 2 quarters · filed 2025-05-14 | $722.00K derived: sum of 3 quarters · filed 2025-05-14 | $837.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $531.00K derived: sum of 2 quarters · filed 2025-03-28 | $646.00K derived: sum of 3 quarters · filed 2025-03-28 | $293.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $290.00K derived: sum of 2 quarters · filed 2024-11-12 | -$63.00K 10-Q · filed 2024-11-12 | $432.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$238.00K 10-Q · filed 2024-08-13 | $257.00K derived: sum of 3 quarters · filed 2024-08-13 | $192.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$353.00K 10-Q · filed 2024-05-10 | $142.00K derived: sum of 2 quarters · filed 2024-05-10 | $77.00K derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $430.00K derived: sum of 2 quarters · filed 2024-02-20 | $424.00K 10-K · filed 2024-02-20 | |
| 2022-09-30 | -$65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$71.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$6.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |